Advertisement

Gynecological Cancers

  • Melis GultekinEmail author
  • Sezin Yuce Sari
  • Gozde Yazici
  • Pervin Hurmuz
  • Ferah Yildiz
  • Gokhan Ozyigit
Chapter

Abstract

This chapter on gynecological cancers is aiming to summarize the evidence-based current management for endometrial, cervical and vulvar cancer. We hope to ease the understanding in the appropriate delineation of tumor volumes/fields along with related case presentations covering diagnostic images, contouring, slice by slice final plan examples; accompanied by up-to-date key literature review.

References

  1. 1.
    Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107–8.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Cibula D, Potter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol. 2018;28(4):641–55.Google Scholar
  3. 3.
    Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19(17):3745–9.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Scheidler J, Hricak H, Yu KK, Subak L, Segal MR. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA. 1997;278(13):1096–101.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Leblanc E, Gauthier H, Querleu D, et al. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma. Ann Surg Oncol. 2011;18(8):2302–9.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Ramirez PT, Jhingran A, Macapinlac HA, et al. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011;117(9):1928–34.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Cormier B, Diaz JP, Shih K, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol. 2011;122(2):275–80.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Robison K, Holman LL, Moore RG. Update on sentinel lymph node evaluation in gynecologic malignancies. Curr Opin Obstet Gynecol. 2011;23(1):8–12.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Mota F. Microinvasive squamous carcinoma of the cervix: treatment modalities. Acta Obstet Gynecol Scand. 2003;82(6):505–9.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350(9077):535–40.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, Wright JD. Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol. 2009;201(5):485.e481–9.CrossRefGoogle Scholar
  12. 12.
    Donovan KA, Taliaferro LA, Alvarez EM, Jacobsen PB, Roetzheim RG, Wenham RM. Sexual health in women treated for cervical cancer: characteristics and correlates. Gynecol Oncol. 2007;104(2):428–34.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Shimada M, Kigawa J, Nishimura R, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol. 2006;101(2):234–7.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;73(2):177–83.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65(1):169–76.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Rogers L, Siu SS, Luesley D, Bryant A, Dickinson HO. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev. 2012;5:CD007583.PubMedCentralGoogle Scholar
  17. 17.
    Okazawa M, Mabuchi S, Isohashi F, et al. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer. 2013;23(3):567–75.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Ryu SY, Kim MH, Nam BH, et al. Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study. Br J Cancer. 2014;110(2):278–85.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606–13.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Monk BJ, Wang J, Im S, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol. 2005;96(3):721–8.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Feng SY, Zhang YN, Liu JG. Risk factors and prognosis of node-positive cervical carcinoma. Ai Zheng. 2005;24(10):1261–6.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Yessaian A, Magistris A, Burger RA, Monk BJ. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol. 2004;94(1):61–6.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Yamashita H, Okuma K, Kawana K, et al. Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study. Am J Clin Oncol. 2010;33(6):583–6.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–61.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137–43.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339–48.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Thomas GM. Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340(15):1198–200.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Chemoradiotherapy for Cervical Cancer Meta-analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010;1:CD008285.Google Scholar
  30. 30.
    Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872–80.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Stehman FB, Ali S, Keys HM, et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007;197(5):503.e501–6.CrossRefGoogle Scholar
  32. 32.
    Chemoradiotherapy for Cervical Cancer Meta-Analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802–12.CrossRefGoogle Scholar
  33. 33.
    King M, McConkey C, Latief TN, Hartley A, Fernando I. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol. 2006;18(1):38–45.CrossRefGoogle Scholar
  34. 34.
    Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25(20):2952–65.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol. 2008;108(1):195–200.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Wang CC, Chou HH, Yang LY, et al. A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic Oncology Group study. Gynecol Oncol. 2015;137(3):462–7.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Thakur P, Seam R, Gupta M, Gupta M. Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly cisplatin in locally advanced carcinoma cervix. Ann Transl Med. 2016;4(3):48.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Duenas-Gonzalez A, Zarba JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29(13):1678–85.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Rose PG, Degeest K, McMeekin S, Fusco N. A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;107(2):274–9.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Cosin JA, Fowler JM, Chen MD, Paley PJ, Carson LF, Twiggs LB. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer. 1998;82(11):2241–8.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Goff BA, Muntz HG, Paley PJ, Tamimi HK, Koh WJ, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol. 1999;74(3):436–42.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Gold MA, Tian C, Whitney CW, Rose PG, Lanciano R. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Cancer. 2008;112(9):1954–63.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Zanvettor PH, Filho DF, Neves AR, et al. Laparoscopic surgical staging of locally advanced cervix cancer (IB2 to IVA): initial experience. Gynecol Oncol. 2011;120(3):358–61.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Moore KN, Gold MA, McMeekin DS, Walker JL, Rutledge T, Zorn KK. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol. 2008;108(3):466–71.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Sonoda Y, Leblanc E, Querleu D, et al. Prospective evaluation of surgical staging of advanced cervical cancer via a laparoscopic extraperitoneal approach. Gynecol Oncol. 2003;91(2):326–31.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Weiser EB, Bundy BN, Hoskins WJ, et al. Extraperitoneal versus transperitoneal selective paraaortic lymphadenectomy in the pretreatment surgical staging of advanced cervical carcinoma (a Gynecologic Oncology Group study). Gynecol Oncol. 1989;33(3):283–9.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Grigsby PW, Lu JD, Mutch DG, Kim RY, Eifel PJ. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: phase II study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys. 1998;41(4):817–22.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Varia MA, Bundy BN, Deppe G, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998;42(5):1015–23.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Small W Jr, Winter K, Levenback C, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68(4):1081–7.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Grigsby PW, Heydon K, Mutch DG, Kim RY, Eifel P. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001;51(4):982–7.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Rotman M, Choi K, Guse C, Marcial V, Hornback N, John M. Prophylactic irradiation of the para-aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. Int J Radiat Oncol Biol Phys. 1990;19(3):513–21.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA. 1995;274(5):387–93.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Morice P, Rouanet P, Rey A, et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist. 2012;17(1):64–71.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Darus CJ, Callahan MB, Nguyen QN, et al. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer. 2008;18(4):730–5.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol. 2003;89(3):343–53.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Kokka F, Bryant A, Brockbank E, Powell M, Oram D. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev. 2015;4:CD010260.Google Scholar
  57. 57.
    Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol. 2013;39(2):115–24.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Landoni F, Sartori E, Maggino T, et al. Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecol Oncol. 2014;132(3):611–7.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Ye Q, Yuan HX, Chen HL. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis. J Cancer Res Clin Oncol. 2013;139(11):1887–98.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36:1548–55.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Pahisa J, Martinez-Roman S, Martinez-Zamora MA, et al. Laparoscopic ovarian transposition in patients with early cervical cancer. Int J Gynecol Cancer. 2008;18(3):584–9.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Small W Jr, Mell LK, Anderson P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):428–34.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Folkert MR, Shih KK, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Gynecol Oncol. 2013;128(2):288–93.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Du XL, Sheng XG, Jiang T, et al. Intensity-modulated radiation therapy versus para-aortic field radiotherapy to treat para-aortic lymph node metastasis in cervical cancer: prospective study. Croat Med J. 2010;51(3):229–36.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Lim K, Small W Jr, Portelance L, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys. 2011;79(2):348–55.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;87(1):111–9.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Parker K, Gallop-Evans E, Hanna L, Adams M. Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution. Int J Radiat Oncol Biol Phys. 2009;74(1):140–6.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Hellebust TP, Kristensen GB, Olsen DR. Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly. Int J Radiat Oncol Biol Phys. 2010;76(3):713–8.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Liu R, Wang X, Tian JH, et al. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev. 2014;10:CD007563.Google Scholar
  70. 70.
    ICRU. International Commission of Radiation Units and Measurements. Dose and volume specification for reporting intracavitary therapy in gynaecology. ICRU Report 38, Bethesda, MD; 1985.Google Scholar
  71. 71.
    Zwahlen D, Jezioranski J, Chan P, et al. Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix. Int J Radiat Oncol Biol Phys. 2009;74(4):1157–64.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78(1):67–77.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74(3):235–45.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Charra-Brunaud C, Harter V, Delannes M, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol. 2012;103(3):305–13.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Potter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007;83(2):148–55.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Castelnau-Marchand P, Chargari C, Maroun P, et al. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer. Gynecol Oncol. 2015;139(2):288–94.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Lindegaard JC, Fokdal LU, Nielsen SK, Juul-Christensen J, Tanderup K. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol. 2013;52(7):1510–9.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Rijkmans EC, Nout RA, Rutten IH, et al. Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol Oncol. 2014;135(2):231–8.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Viswanathan AN, Erickson B, Gaffney DK, et al. Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2014;90(2):320–8.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Viswanathan AN, Dimopoulos J, Kirisits C, Berger D, Potter R. Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys. 2007;68(2):491–8.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Ohno T, Wakatsuki M, Toita T, et al. Recommendations for high-risk clinical target volume definition with computed tomography for three-dimensional image-guided brachytherapy in cervical cancer patients. J Radiat Res. 2017;58(3):341–50.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Song S, Rudra S, Hasselle MD, et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer. 2013;119(2):325–31.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Nugent EK, Case AS, Hoff JT, et al. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol. 2010;116(3):438–41.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Nag S, Chao C, Erickson B, et al. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2002;52(1):33–48.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Viswanathan AN, Beriwal S, De Los Santos JF, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012;11(1):47–52.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    International Commission on Radiation Units and Measurements. Prescribing R, and reporting brachytherapy for cancer of the cervix (ICRU report 89), Bethesda, 2016.Google Scholar
  87. 87.
    Potter R, Georg P, Dimopoulos JC, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol. 2011;100(1):116–23.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Potter R, Tanderup K, Kirisits C, et al. The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48–60.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M, Gynecology Cancer Disease Site G. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol. 2009;114(3):528–35.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–78.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    American College of O, Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005;106(2):413–25.CrossRefGoogle Scholar
  92. 92.
    Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103–4.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Aalders JG, Thomas G. Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes. Gynecol Oncol. 2007;104(1):222–31.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Homesley HD, Kadar N, Barrett RJ, Lentz SS. Selective pelvic and periaortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. Am J Obstet Gynecol. 1992;167(5):1225–30.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Franchi M, Ghezzi F, Riva C, Miglierina M, Buttarelli M, Bolis P. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. J Surg Oncol. 2001;78(4):232–7. discussion 237–40PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Russell AH. Forwards through the rear-view mirror. Gynecol Oncol. 2009;115(1):1–3.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Benedet JL. Editorial. Int J Gynaecol Obstet. 2000;70(2):207–8.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Frederick PJ, Straughn JM Jr. The role of comprehensive surgical staging in patients with endometrial cancer. Cancer Control. 2009;16(1):23–9.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707–16.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK, AS Group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer. 1987;60(8 Suppl):2035–41.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Manfredi R, Mirk P, Maresca G, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology. 2004;231(2):372–8.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Akin O, Mironov S, Pandit-Taskar N, Hann LE. Imaging of uterine cancer. Radiol Clin N Am. 2007;45(1):167–82.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Sorbe B, Nordstrom B, Maenpaa J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009;19(5):873–8.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40(1):55–65.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Eifel PJ, Ross J, Hendrickson M, Cox RS, Kempson R, Martinez A. Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer. 1983;52(6):1026–31.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–51.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012;4:CD003916.PubMedCentralGoogle Scholar
  110. 110.
    Onsrud M, Cvancarova M, Hellebust TP, Trope CG, Kristensen GB, Lindemann K. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol. 2013;31(31):3951–6.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Blake P, Swart AM, Group AES, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137–46.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355(9213):1404–11.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(21):1625–34.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–23.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Creutzberg CL, van Putten WL, Koper PC, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2001;51(5):1246–55.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e631–8.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Klopp AH, Jhingran A, Ramondetta L, Lu K, Gershenson DM, Eifel PJ. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009;115(1):6–11.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Alvarez Secord A, Havrilesky LJ, Bae-Jump V, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007;107(2):285–91.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Frigerio L, Mangili G, Aletti G, et al. Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol. 2001;81(1):53–7.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006;103(1):155–9.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Lupe K, D'Souza DP, Kwon JS, et al. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer. Gynecol Oncol. 2009;114(1):94–8.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Onda T, Yoshikawa H, Mizutani K, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer. 1997;75(12):1836–41.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Lupe K, Kwon J, D'Souza D, et al. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int J Radiat Oncol Biol Phys. 2007;67(1):110–6.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev. 2011;10:CD003175.Google Scholar
  125. 125.
    McMeekin DSFV, Aghajanian C, et al. Randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/ carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol Oncol. 2014;134:438.CrossRefGoogle Scholar
  126. 126.
    Randall MEFV, McMeekin DS, et al. A phase 3 trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: a Gynecology Oncology Group study. Int J Radiat Oncol Biol Phys. 2017;99(5):1313.CrossRefGoogle Scholar
  127. 127.
    Parthasarathy A, Kapp DS, Cheung MK, Shin JY, Osann K, Chan JK. Adjuvant radiotherapy in incompletely staged IC and II endometrioid uterine cancer. Obstet Gynecol. 2007;110(6):1237–43.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63(3):834–8.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36–44.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):226–33.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95(3):266–71.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010;46(13):2422–31.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev. 2014;5:CD010681.Google Scholar
  134. 134.
    Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol. 1990;36(2):166–71.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Matei DFV, Randall M, Steinhoff M, DiSilvestro P, Moxley KM. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol. 2017;35:5505.CrossRefGoogle Scholar
  136. 136.
    Kuoppala T, Maenpaa J, Tomas E, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol. 2008;110(2):190–5.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56(4):419–27.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Park HJ, Nam EJ, Kim S, Kim YB, Kim YT. The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):39–44.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Secord AA, Havrilesky LJ, O'Malley DM, et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol. 2009;114(3):442–7.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Abaid LN, Rettenmaier MA, Brown JV, et al. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. J Gynecol Oncol. 2012;23(1):22–7.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol. 2011;121(1):112–7.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Gao H, Zhang Z. Sequential chemotherapy and radiotherapy in the sandwich method for advanced endometrial cancer: a meta-analysis. Medicine (Baltimore). 2015;94(16):e672.CrossRefGoogle Scholar
  143. 143.
    de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295–309.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    de Boer SM, Powell ME, Mileshkin L, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(8):1114–26.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Wright JD, Fiorelli J, Kansler AL, et al. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol. 2009;200(4):419.e411–7.CrossRefGoogle Scholar
  146. 146.
    Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014;4(3):137–44.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Rossi PJ, Jani AB, Horowitz IR, Johnstone PA. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis. Int J Radiat Oncol Biol Phys. 2008;70(1):134–8.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Randall ME, Wilder J, Greven K, Raben M. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1990;19(1):49–54.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Greven K, Winter K, Underhill K, et al. Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2004;59(1):168–73.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Scotti V, Borghesi S, Meattini I, et al. Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence. Int J Gynecol Cancer. 2010;20(9):1540–8.PubMedPubMedCentralGoogle Scholar
  151. 151.
    Jobsen JJ, Lybeert ML, van der Steen-Banasik EM, et al. Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma. Int J Gynecol Cancer. 2008;18(5):1071–8.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Crosby MA, Tward JD, Szabo A, Lee CM, Gaffney DK. Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma? Am J Clin Oncol. 2010;33(4):364–9.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study. Int J Radiat Oncol Biol Phys. 2012;82(3):1249–55.PubMedCrossRefPubMedCentralGoogle Scholar
  154. 154.
    Hasegawa K, Nagao S, Yasuda M, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S90–5.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol. 2011;123(3):542–7.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Barney BM, Petersen IA, Mariani A, Dowdy SC, Bakkum-Gamez JN, Haddock MG. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys. 2013;85(1):109–15.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Bernardini MQ, Gien LT, Lau S, et al. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol. 2016;141(1):148–54.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Podzielinski I, Randall ME, Breheny PJ, et al. Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. Gynecol Oncol. 2012;124(1):36–41.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Fishman DA, Roberts KB, Chambers JT, Kohorn EI, Schwartz PE, Chambers SK. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol. 1996;61(2):189–96.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Patsavas K, Woessner J, Gielda B, et al. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol Oncol. 2011;121(3):581–5.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Rauh-Hain JA, Growdon WB, Schorge JO, et al. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol. 2010;119(2):299–304.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Shih KK, Yun E, Gardner GJ, Barakat RR, Chi DS, Leitao MM Jr. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol. 2011;122(3):608–11.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000;78(2):85–91.PubMedCrossRefPubMedCentralGoogle Scholar
  164. 164.
    Beriwal S, Jain SK, Heron DE, et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol. 2006;102(2):195–9.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Small W Jr, Beriwal S, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy. 2012;11(1):58–67.PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    Schwarz JK, Beriwal S, Esthappan J, et al. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy. 2015;14(5):587–99.PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    Viswanathan C, Kirschner K, Truong M, Balachandran A, Devine C, Bhosale P. Multimodality imaging of vulvar cancer: staging, therapeutic response, and complications. AJR Am J Roentgenol. 2013;200(6):1387–400.PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    van der Velden J, Fons G, Lawrie TA. Primary groin irradiation versus primary groin surgery for early vulvar cancer. Cochrane Database Syst Rev. 2011;5:CD002224.Google Scholar
  169. 169.
    DeSimone CP, Van Ness JS, Cooper AL, et al. The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus. Gynecol Oncol. 2007;104(2):390–5.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Ansink A, van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database Syst Rev. 2000;2:CD002036.Google Scholar
  171. 171.
    Farias-Eisner R, Cirisano FD, Grouse D, et al. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. Gynecol Oncol. 1994;53(1):55–8.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Leuchter RS. Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol. 1984;63(2):155–62.PubMedPubMedCentralGoogle Scholar
  173. 173.
    Woelber L, Eulenburg C, Grimm D, et al. The risk of contralateral non-sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node. Ann Surg Oncol. 2016;23(8):2508–14.PubMedCrossRefPubMedCentralGoogle Scholar
  174. 174.
    Coleman RL, Ali S, Levenback CF, et al. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol. 2013;128(2):155–9.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Gonzalez Bosquet J, Magrina JF, Magtibay PM, et al. Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva. Gynecol Oncol. 2007;105(3):742–6.PubMedCrossRefPubMedCentralGoogle Scholar
  176. 176.
    Burger MP, Hollema H, Emanuels AG, Krans M, Pras E, Bouma J. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol. 1995;57(3):327–34.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26(6):884–9.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012;30(31):3786–91.PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Oonk MH, van Hemel BM, Hollema H, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol. 2010;11(7):646–52.PubMedCrossRefPubMedCentralGoogle Scholar
  180. 180.
    Covens A, Vella ET, Kennedy EB, Reade CJ, Jimenez W, Le T. Sentinel lymph node biopsy in vulvar cancer: Systematic review, meta-analysis and guideline recommendations. Gynecol Oncol. 2015;137(2):351–61.PubMedCrossRefPubMedCentralGoogle Scholar
  181. 181.
    Stehman FB, Bundy BN, Thomas G, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1992;24(2):389–96.PubMedCrossRefPubMedCentralGoogle Scholar
  182. 182.
    Hallak S, Ladi L, Sorbe B. Prophylactic inguinal-femoral irradiation as an alternative to primary lymphadenectomy in treatment of vulvar carcinoma. Int J Oncol. 2007;31(5):1077–85.PubMedPubMedCentralGoogle Scholar
  183. 183.
    Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol. 1990;38(3):309–14.PubMedCrossRefPubMedCentralGoogle Scholar
  184. 184.
    Ignatov T, Eggemann H, Burger E, Costa SD, Ignatov A. Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins. J Cancer Res Clin Oncol. 2016;142(2):489–95.PubMedCrossRefPubMedCentralGoogle Scholar
  185. 185.
    Chapman BV, Gill BS, Viswanathan AN, Balasubramani GK, Sukumvanich P, Beriwal S. Adjuvant radiation therapy for margin-positive vulvar squamous cell carcinoma: defining the ideal dose-response using the national cancer data base. Int J Radiat Oncol Biol Phys. 2017;97(1):107–17.PubMedCrossRefPubMedCentralGoogle Scholar
  186. 186.
    Te Grootenhuis NC, Pouwer AW, de Bock GH, et al. Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: a systematic review. Gynecol Oncol. 2018;148(3):622–31.CrossRefGoogle Scholar
  187. 187.
    Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 1992;79(4):490–7.PubMedPubMedCentralGoogle Scholar
  188. 188.
    Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst. 2015;107(3):dju426.PubMedPubMedCentralCrossRefGoogle Scholar
  189. 189.
    Chan JK, Sugiyama V, Pham H, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol. 2007;104(3):636–41.PubMedCrossRefPubMedCentralGoogle Scholar
  190. 190.
    Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. 1986;68(6):733–40.PubMedPubMedCentralGoogle Scholar
  191. 191.
    Parthasarathy A, Cheung MK, Osann K, et al. The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol. 2006;103(3):1095–9.PubMedCrossRefPubMedCentralGoogle Scholar
  192. 192.
    Fons G, Groenen SM, Oonk MH, et al. Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial. Gynecol Oncol. 2009;114(2):343–5.PubMedCrossRefPubMedCentralGoogle Scholar
  193. 193.
    Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol. 2009;114(3):537–46.PubMedCrossRefPubMedCentralGoogle Scholar
  194. 194.
    Gill BS, Bernard ME, Lin JF, et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. Gynecol Oncol. 2015;137(3):365–72.PubMedCrossRefPubMedCentralGoogle Scholar
  195. 195.
    Dusenbery KE, Carlson JW, LaPorte RM, et al. Radical vulvectomy with postoperative irradiation for vulvar cancer: therapeutic implications of a central block. Int J Radiat Oncol Biol Phys. 1994;29(5):989–98.PubMedCrossRefPubMedCentralGoogle Scholar
  196. 196.
    Boronow RC. Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer: rationale and results. Cancer. 1982;49(6):1085–91.PubMedCrossRefPubMedCentralGoogle Scholar
  197. 197.
    Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. Cochrane Database Syst Rev. 2011;4:CD003752.Google Scholar
  198. 198.
    Han SC, Kim DH, Higgins SA, Carcangiu ML, Kacinski BM. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys. 2000;47(5):1235–44.PubMedCrossRefPubMedCentralGoogle Scholar
  199. 199.
    Nooij LS, Ongkiehong PJ, van Zwet EW, et al. Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma. Gynecol Oncol. 2015;139(3):458–64.PubMedCrossRefPubMedCentralGoogle Scholar
  200. 200.
    Hyde SE, Valmadre S, Hacker NF, Schilthuis MS, Grant PT, van der Velden J. Squamous cell carcinoma of the vulva with bulky positive groin nodes-nodal debulking versus full groin dissection prior to radiation therapy. Int J Gynecol Cancer. 2007;17(1):154–8.PubMedCrossRefPubMedCentralGoogle Scholar
  201. 201.
    Moore DH, Ali S, Koh WJ, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;124(3):529–33.PubMedCrossRefPubMedCentralGoogle Scholar
  202. 202.
    Stecklein SR, Frumovitz M, Klopp AH, Gunther JR, Eifel PJ. Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. Gynecol Oncol. 2018;148(3):474–9.PubMedCrossRefPubMedCentralGoogle Scholar
  203. 203.
    Reade CJ, Eiriksson LR, Mackay H. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecol Oncol. 2014;132(3):780–9.PubMedCrossRefPubMedCentralGoogle Scholar
  204. 204.
    van Doorn HC, Ansink A, Verhaar-Langereis M, Stalpers L. Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev. 2006;3:CD003752.Google Scholar
  205. 205.
    Eifel PJ, Morris M, Burke TW, Levenback C, Gershenson DM. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol. 1995;59(1):51–6.PubMedCrossRefPubMedCentralGoogle Scholar
  206. 206.
    Lupi G, Raspagliesi F, Zucali R, et al. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. Cancer. 1996;77(8):1472–8.PubMedCrossRefPubMedCentralGoogle Scholar
  207. 207.
    Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42(1):79–85.PubMedCrossRefPubMedCentralGoogle Scholar
  208. 208.
    Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol. 2006;100(1):53–7.PubMedCrossRefPubMedCentralGoogle Scholar
  209. 209.
    Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol. 1996;61(3):321–7.PubMedCrossRefPubMedCentralGoogle Scholar
  210. 210.
    Berek JS, Heaps JM, Fu YS, Juillard GJ, Hacker NF. Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol. 1991;42(3):197–201.PubMedCrossRefPubMedCentralGoogle Scholar
  211. 211.
    Koh WJ, Wallace HJ, Greer BE, et al. Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. Int J Radiat Oncol Biol Phys. 1993;26(5):809–16.PubMedCrossRefPubMedCentralGoogle Scholar
  212. 212.
    Cunningham MJ, Goyer RP, Gibbons SK, Kredentser DC, Malfetano JH, Keys H. Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol. 1997;66(2):258–61.PubMedCrossRefPubMedCentralGoogle Scholar
  213. 213.
    Gerszten K, Selvaraj RN, Kelley J, Faul C. Preoperative chemoradiation for locally advanced carcinoma of the vulva. Gynecol Oncol. 2005;99(3):640–4.PubMedCrossRefPubMedCentralGoogle Scholar
  214. 214.
    Tans L, Ansink AC, van Rooij PH, Kleijnen C, Mens JW. The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. Am J Clin Oncol. 2011;34(1):22–6.PubMedCrossRefPubMedCentralGoogle Scholar
  215. 215.
    Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 2000;48(4):1007–13.PubMedCrossRefPubMedCentralGoogle Scholar
  216. 216.
    Stehman FB, Look KY. Carcinoma of the vulva. Obstet Gynecol. 2006;107(3):719–33.PubMedCrossRefPubMedCentralGoogle Scholar
  217. 217.
    Beriwal S, Shukla G, Shinde A, et al. Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse. Int J Radiat Oncol Biol Phys. 2013;85(5):1269–74.PubMedCrossRefPubMedCentralGoogle Scholar
  218. 218.
    Kim CH, Olson AC, Kim H, Beriwal S. Contouring inguinal and femoral nodes; how much margin is needed around the vessels? Pract Radiat Oncol. 2012;2(4):274–8.PubMedCrossRefPubMedCentralGoogle Scholar
  219. 219.
    Jackson KS, Fankam EF, Das N, et al. Unilateral groin and pelvic irradiation for unilaterally node-positive women with vulval carcinoma. Int J Gynecol Cancer. 2006;16(1):283–7.PubMedCrossRefPubMedCentralGoogle Scholar
  220. 220.
    Gaffney DK, King B, Viswanathan AN, et al. Consensus recommendations for radiation therapy contouring and treatment of vulvar carcinoma. Int J Radiat Oncol Biol Phys. 2016;95(4):1191–200.PubMedPubMedCentralCrossRefGoogle Scholar
  221. 221.
    Beriwal S, Heron DE, Kim H, et al. Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. Int J Radiat Oncol Biol Phys. 2006;64(5):1395–400.PubMedCrossRefPubMedCentralGoogle Scholar
  222. 222.
    Viswanathan AN, Pinto AP, Schultz D, Berkowitz R, Crum CP. Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol. 2013;130(3):545–9.PubMedCrossRefPubMedCentralGoogle Scholar
  223. 223.
    Rao YJ, Chin RI, Hui C, et al. Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: a review of the National Cancer Database. Gynecol Oncol. 2017;146(3):572–9.PubMedCrossRefPubMedCentralGoogle Scholar
  224. 224.
    Oonk MHM, Planchamp F, Baldwin P, et al. European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer. Int J Gynecol Cancer. 2017;27(4):832–7.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Melis Gultekin
    • 1
    Email author
  • Sezin Yuce Sari
    • 1
  • Gozde Yazici
    • 1
  • Pervin Hurmuz
    • 1
  • Ferah Yildiz
    • 1
  • Gokhan Ozyigit
    • 1
  1. 1.Department of Radiation Oncology, Faculty of MedicineHacettepe UniversityAnkaraTurkey

Personalised recommendations